SymBio Pharmaceuticals Limited
【SymBio Pharmaceutical】Exercise of Stock Acquisition Rights in Large Volume｜July 2026
As of July 29, 2026, SymBio Pharmaceutical transferred 28,540 shares through the exercise of stock acquisition rights, bringing the total issued shares to approximately 76,434,210.
Key Figures
- Total Issued Shares: 76,434,210 shares
- Shares Delivered Since the Beginning of the Month: 3,794,000 shares
- Number of Stock Acquisition Rights Exercised Since the Beginning of the Month: 37,940 units
AI要約
Overview of Exercise Status
SymBio Pharmaceutical announced the exercise status of the 66th stock acquisition rights issued in August 2025. Between July 1 and 29, 2026, 37,940 stock acquisition rights were exercised, and 28,540 new shares were transferred. As a result, the remaining unexercised stock acquisition rights totaled 120,510 units. The exercise rate was 19.0%, and unexercised rights continue to exist.
Impact on Shareholders and Future Outlook
Although the total issued shares increased due to the exercise of the stock acquisition rights, the dilution of shares is considered limited. While ongoing monitoring of the exercise status is necessary, no significant impact on business performance has been observed at this time. Continued attention to exercise trends and capital policy developments is required in the future.
SymBio Pharmaceutical Limited
Company overview · Stock price · Financial data · All IR
